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Parkinson’s Disease (PD) is a common neurodegenerative disorder and the leading cause
of disability. It causes significant morbidity and disability through a plethora of
symptoms, including movement disorders, sleep disturbances, and cognitive and
psychiatric symptoms. The traditional pathogenesis theory of PD involves the loss of
dopaminergic neurons in the substantia nigra (SN). Classically, treatment is pursued with
an assortment of medications that are directed at overcoming this deficiency with
levodopa being central to most treatment plans. Patients taking levodopa tend to
experience “off episodes” with decreasing medication levels, causing large fluctuations in
their symptoms. These off episodes are disturbing and a source of morbidity for these
patients. Opicapone is a novel, peripherally acting Catechol-O-methyl transferase
(COMT) inhibitor that is used as adjunctive therapy to carbidopa/levodopa for treatment
and prevention of “off episodes.” It has been approved for use as an adjunct to levodopa
since 2016 in Europe and has recently (April 2020) gained FDA approval for use in the
USA. By inhibiting COMT, opicapone slows levodopa metabolism and increases its
availability. Several clinical studies demonstrated significant improvement in treatment
efficacy and reduction in duration of “off episodes.” The main side effect demonstrated
was dyskinesia, mostly with the 100mg dose, which is higher than the approved, effective
dose of 50mg. Post-marketing surveillance and analysis are required to further elucidate
its safety profile and contribute to patient selection. This paper reviews the seminal and
latest evidence in the treatment of PD “off episodes” with the novel drug Opicapone,
including efficacy, safety, and clinical indications.

INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative disease associated with the accumulation of α-synuclein protein in
nuclei of the substantia nigra (SN) of the brainstem and the
cortex. The clinical presentation includes stereotyped motor symptoms of tremor, rigidity, bradykinesia, and postural
instability.1 In addition, non-motor symptoms can manifest, including hyposmia or anosmia, genitourinary complications, constipation, cognitive impairment, psychiatric
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issues, and rapid eye movement (REM) sleep behavior disorder.2
PD is a common disorder and the fastest-growing neurodegenerative disorder. In North America alone, the prevalence of PD in 2020 is estimated to be 572 individuals per
100,000, approximately 930,000 Americans.3 The mean age
at diagnosis is 70.5 years.4 Starting from age 50, a higher
prevalence has been cited in men.5
Patients with PD taking long-term levodopa, the most
common therapy, experience fluctuations throughout the
day in the presence and intensity of symptoms. Typically,

the recurrence of symptoms is mitigated after a new dose of
medication.6 These end-of-dose deteriorations, or wearing
“off” states, are classically described by motor complications such as rest tremor, bradykinesia, and rigidity.7,8 Nonmotor fluctuations, such as anxiety, mood changes, hyperhidrosis, slowed cognition, fatigue, and akathisia, may also
manifest.9,10 Off episodes have been traced as a key factor
in health-related quality of life reporting.11
There is a large variation in the time it takes for “off”
episodes to develop in the patient throughout the course
of PD treatment. These symptoms present in 30% of patients in as little as 40 weeks of treatment; in others (about
40% of patients), they only appear after 4-6 years of treatment.12,13 Another study showed that off episode frequency
increased to 76.2% in patients living with the disease for
10-15 years.14 Typically, younger age of PD onset, female
gender, and higher dose of levodopa predispose towards
higher rates of motor fluctuations.15,16 Genetic variations,
differences in comorbidities, and availability of adjunctive
therapies can also influence the onset of the off episodes.17
About 75% of motor fluctuations also present with nonmotor symptoms.10 Some studies show up to 40% of all patients with PD report an experience of anxiety that disrupts
daily life.18
Opicapone (Ongentys) is a novel Catechol-O-methyl
transferase (COMT) inhibitor, used as adjunctive treatment
with levodopa and the carbidopa/levodopa combination in
patients with PD experiencing “off episodes.” The background, indications, and clinical data surrounding its use
are reviewed in this paper.

METHODS
We conducted literature searches using PubMed and Google
Scholar between 2020-2021. Articles were chosen based on
relevance to Opicapone and its therapeutic effects on
Parkinsonism. We selected primary literature as well as
clinical trial studies to reflect the validity of the review.
Older articles were included as well to refer to previous
background information.
The PubMed and Google Scholar keywords searched were
as follows: Parkinsonism, Parkinson’s disease, opicapone,
neurodegenerative disease, and COMT inhibitor.

PARKINSON’S DISEASE
Parkinson’s disease (PD) is a vanguard among parkinsonism. It is a neurodegenerative disease associated with an accumulation of α-synuclein protein, or Lewy bodies, in nuclei of the substantia nigra (SN) of the brainstem and in the
cortex. These aggregates can also be found in regions of the
enteric and peripheral nervous system.19
EPIDEMIOLOGY

Per the 2016 Global Burden of Disease, neurological disorders have become the leading cause of disability, and PD
is the fastest growing among them. Since PD prevalence
increases with age, the burden of disease falls heavily on
aging populations.20,21 The mean age at diagnosis is 70.5

years.4 Between 1990 and 2016, the global burden of PD has
more than doubled from 2.5 million patients to 6.1 million
patients.20 In North America alone, the prevalence in 2020
is estimated to be 572 individuals per 100,000 or approximately 930,000 Americans.3 Starting from age 50, a higher
prevalence of PD has been cited in men.5 However, this gender-based divergence remains poorly understood in light of
multifactorial risk factors and emerging disease subtypes.22
PATHOPHYSIOLOGY

The loss of dopaminergic neurons has been suggested to
be the primary factor for motor symptoms, whereas the
death of cholinergic, serotonergic, and noradrenergic neurons may be responsible for cognitive, psychiatric, and
other prodromal changes.23,24 An oft-cited hypothesis of
disease onset describes the course of PD over six stages with
the earliest dysfunction beginning at the olfactory bulb and
the medulla.25 In the early stages, patients may experience
hyposmia, gastrointestinal difficulties, such as constipation, and REM sleep disorders. The stereotyped motor function loss results from the decay of neurons in the pars compacta in SN and other components of the basal ganglia and
midbrain over the course of stages 3 and 4. The late-stage
disease presents with hallucinations and further cognitive
decline due to widespread cortical progression. Alternative
hypotheses have been proposed reconsidering the directionality of α-synuclein aggregation such that in some PD
subtypes, nigrostriatal dopaminergic dysfunction precedes
the involvement of the autonomic nervous system.26
At the cellular level, the pathophysiology of PD overlaps
with numerous molecular pathways associated with the
management of misfolded proteins.27 Gene involvement of
α-synuclein (SNCA) and leucine-rich repeat kinase 2
(LRRK2) implicate the ubiquitin-proteasomal system and
autophagy-lysosomal pathway, respectively.28,29 Mitochondrial dysfunction ranges from impaired mitochondrial
maintenance, defective mitophagy, calcium imbalance, oxidative stress, and neuroinflammation.30–34 These are
thought to be due to the downstream effects of the LRRK2
scaffold upon Parkin (PRKN), PTEN induced putative kinase
1 (PINK1), β-glucocerebrosidase 1 (GBA1) proteins, among
others.35–37 Definitive neuroanatomical models have not
yet been determined to trace pathology up from the cellular
level.38 Recent studies have indicated further molecularlevel gastroenterological associations involving toll-like receptors in the gut microbiome, reactive pleocytosis in the
bowel, and absence of anti-inflammatory, butyrate-producing bacteria.39–43
RISK FACTORS

Genetic inheritance has been demonstrated for PD.44 Multiple inheritance patterns have been shown, and several
nuclear genes are linked to disease progression. While no
conclusive direct relationships have been shown between
environmental triggers, these continue to be a source of
study. The strongest risk factors for late-stage diagnosis of
PD include a family history of either PD or tremor, constipation, and absence of smoking (smoking has a protective role).45 Caffeine may also be protective.1 Other risk fac-
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tors include depression, exposure to pesticides, herbicides,
heavy metals, and high consumption of dairy products.46
Further study of risk factors and the genetic basis of the disease could be useful to the development of disease-modifying therapies or preventative measures.
DIAGNOSIS AND CLINICAL PRESENTATION

PD is best known for its characteristic movement abnormalities, such as resting tremor, bradykinesia, rigidity, decreased coordination, postural instability, and abnormal
gait.1 In addition to these classic symptoms, current clinical
practice appreciates many non-motor symptoms, including
hyposmia or anosmia, genitourinary complications, constipation, cognitive impairment, psychiatric issues, and rapid
eye movement (REM) sleep behavior disorder.2 The clinician must apply caution to distinguish resting tremors from
essential tremors and re-emergent tremors. Resting
tremors in PD occur while the body part is at rest and not
engaged in purposeful action. Re-emergent tremors can be
confused for essential tremors, thereby making PD subtyping more challenging.47 Diagnosis of PD occurs with the
identification of α-synuclein aggregates in the SN, basal
ganglia, midbrain, and regions of the peripheral nervous
system.48 While the gold standard remains the identification of the Lewy bodies at post-mortem pathological examination, detection of prodromal symptoms in the pre-motor
phase could prove useful for diagnosis at an earlier stage of
the disease.49,50 Various phenomenological and systematic
categorizations have been made to distinguish subtypes of
PD. These categorizations focus on the rate of disease progression (malignant or mild) on either motor or non-motor
axes, age at onset (below 50 vs. over 50), and responsiveness to medications, such as dopamine replacement therapies.51–53 Molecular-level studies have become more popular in influencing the data-driven clustering of subtypes.27
Some imaging techniques can aid as diagnostic tools in
PD detection: dopamine transport single-photon emission
computed tomography, to distinguish resting tremor in PD
from essential tremor, and magnetic resonance imaging, to
distinguish PD from other parkinsonism syndromes.2 Responsiveness to dopaminergic therapy is a useful diagnostic
marker alongside on-off fluctuations in concert with drug
dosage. There are absolute exclusion criteria to rule out PD:
lack of responsiveness of dopaminergic neurons to highdose levodopa, the responsiveness of these neurons to
dopamine receptor blockers, progressive degeneration in
limb movement coordination, aphasia, or oculomotor abnormalities.24 Red flags such as rapid gait impairment, bulbar dysfunction, severe autonomic failure such as orthostatic hypotension, and severe urinary retention/incontinence
would also exclude PD as the diagnosis.24 Characteristics of
advanced Parkinson’s disease include severe off periods, excessive daytime sleepiness, difficulties in ambulation, impaired cognition and/or presence of psychiatric symptoms,
dysphagia, dysarthria, and required assistance for mundane
activities.53 Often, the difficulties in ambulation manifest
as freezing of gait, impairments in balance, dyskinesia, and
recurrent falls.24 These, along with psychiatric symptoms
such as hallucinations, psychosis, depression, and apathy,

predicate the need for a caregiver or placement at nursing
homes.54

CURRENT TREATMENT OPTIONS
Parkinson’s Disease (PD) is usually the result of balancing
treatment effects and disease impact on daily life.2 There
are both pharmacologic and nonpharmacologic treatment
options for patients, and these may also be combined and
tailored to disease severity and individual choice.2
CONSERVATIVE TREATMENT

Nonpharmacologic treatment, including aerobic exercise or
physical therapy, is initiated at diagnosis and should be
continued throughout the disease course. Moderate-intensity aerobic exercise, defined as achieving >60% maximum
heart rate for four days per week for six months, has shown
a positive impact on the clinical course of PD.55 Although
exercise does not slow the progression of akinesia or rigidity, it has been shown to alleviate secondary symptoms such
as flexed posture and nonmotor symptoms, as well as ameliorate motor tasks.55,56 A recent study investigating the
effects of high-intensity treadmill training found that motor function worsened significantly less over the span of 6
months in the exercise group when compared to the control
group.57
PHARMACOLOGICAL THERAPY

There are several pharmacologic classes of PD treatment,
including monoamine oxidase type B (MAO-B) inhibitors,
adamantanes (amantadine), dopamine agonists (DAs), levodopa, anticholinergics, and Catechol-O-methyl transferase (COMT) inhibitors. MAO-B inhibitors such as selegiline, rasagiline, and safinamide are beneficial in early PD
and can be used in patients of any age. Among the MAOB inhibitors, safinamide is used as adjunctive therapy for
levodopa in advanced PD. When combined with levodopa,
MAO-B inhibitors improve the long-term clinical course of
PD as measured by the Unified Parkinson Disease Rating
Scale over the span of 7 years.58 Amantadine affects several
neurotransmitter systems and is used as a monotherapy alternative to MAO-B inhibitors. Amantadine acts by increasing dopamine release, inhibiting dopamine reuptake and
NMDA receptors, stimulating dopamine receptors, and exerting central anticholinergic effects.59 Amantadine is preferentially utilized in tremor-prominent-PD and has been
shown to have greater efficacy in treating rigidity and
bradykinesia than anticholinergic drugs used in PD treatment.60 Non-ergot DAs are preferentially used when motor
symptoms interfere with a patient’s quality of life. They include the oral medications pramipexole and ropinirole, and
the transdermal formulation rotigotine. They are most effective in early disease as monotherapy. Levodopa revolutionized PD treatment over half a century ago, relieving
severely disabled PD patients from their symptoms.61 Levodopa provides a more effective improvement in motor
function and quality of life when compared to Das.12,62–64
Formulations include carbidopa-levodopa (Sinemet) and
benserazide-levodopa (Prolopa), both of which add periph-
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eral decarboxylase inhibitor action, decreasing adverse effects.65 Levodopa is initiated when motor symptoms interfere with the quality of life. Patients less than 65 years of
age with clinically significant tremors and without bradykinesia or gait disturbance can be given anticholinergics. Anticholinergics such as trihexyphenidyl and benztropine can
be useful in patients with persistent tremors already being
treated with DAs or levodopa. COMT inhibitors such as entacapone, tolcapone, and opicapone, potentiate the effect
of levodopa and reduce the 'off-time when Parkinson’s
symptoms return.64 Levodopa dosage should be reduced by
10-30% when combined with COMT inhibitors to avoid
dopaminergic side effects.66
INTERVENTIONAL THERAPY

Deep brain stimulation and MRI-guided focused ultrasounds are surgical treatment options used in patients with
complications and frequent off periods that are non-responsive to medication adjustments.67 Deep brain stimulation requires surgical placement of unilateral/bilateral leads
within the brain. MRI-guided focused ultrasound utilizes
ultrasound beams in order to scar the thalamus while under
MRI monitoring to interrupt the abnormal activity and decrease tremors.67 These methods are useful for patients
with medication-responsive motor symptoms but with
complications such as dyskinesias. These tools can reduce
medication refractory tremors by targeting the thalamus.
LINES AND HIERARCHY OF TREATMENT

Nonpharmacological treatment with or without MAO-B inhibitors is recommended for patients without the significant quality of life impairment.64,68 Patients with motor
symptoms and cognitive impairment should be given levodopa, along with treatment for underlying neurobehavioral dysfunctions. These patients should not receive anticholinergics or amantadine. In patients with pure motor
symptoms, initial therapy should include levodopa preparations, DAs, or MAO-B inhibitors if treating tremor and
bradykinesia, or anticholinergic agents if treating only
tremor. If symptoms continue to progress or the patient experiences “wearing off,” increase the dosages of the previously mentioned medications and/or add amantadine or
COMT inhibitors. Advanced treatment options include levodopa-carbidopa preparations. If the disease continues to
progress even with dose modifications, deep brain stimulation may be used. If the patient experiences tremors
and bradykinesia, a unilateral/bilateral deep brain stimulation of the subthalamic nucleus or globus pallidus interna
should be done. Otherwise, unilaterally focused ultrasound
thalamotomy or deep brain stimulation of the thalamus
may be used for patients experiencing tremors. Finally, exercise and physical therapy should be upheld throughout
the course of the disease to prevent deterioration of the patient’s condition.

headaches, but may also cause confusion and hallucinations in severe cases.69 Amantadine may precipitate livedo
reticularis and ankle edema.70 Anticholinergics result in an
array of adverse effects. Older patients and patients with
cognitive impairments are particularly susceptible to hallucinations, confusion, and memory loss. These antimuscarinics may cause peripheral issues such as dry mouth,
blurred vision, constipation, impaired sweating, and tachycardia.71 Side-effects of levodopa for older patients may include confusion, hallucinations, delusions, agitation, and
psychosis. Adverse effects of DA agonists include hallucinations, hypotension, nausea, vomiting, pathological gambling, compulsive shopping, and hypersexuality.72 The side
effects of COMT inhibitors are commonly due to dopaminergic overstimulation. This may lead to hallucinations,
dyskinesia, or somnolence. Additionally, COMT inhibitors
can cause a benign orange discoloration of urine or diarrhea
which may require drug discontinuation if severe
enough.73,74
An important area where current treatments fall short,
as described above, is the multitude of adverse effects. Additionally, with the progression of the disease, the efficacy
of levodopa decreases and ceases to improve disabling motor and nonmotor features of PD.75 Other interventions
such as COMT inhibitors, MAO-B inhibitors, DAs, and deep
brain stimulation have been used in combination with levodopa to alleviate some of these shortcomings; however,
these drugs are associated with their own side effects as
mentioned above. The drug classes each improve only one
symptom type, making them inefficient.76 Additionally,
novel treatments such gene therapy or targeted molecular
therapy tend to be expensive, complex for patients, or not
available at their facility or in their country. Overall, there
is still a lack of efficacious, cheap, neuroprotective, and
restorative PD treatment, which has led to unmet medical
needs in PD management.75

OPICAPONE
Opicapone, otherwise known as Ongentys®, is a peripherally acting agent that selectively and reversibly binds to
COMT enzymes. It is used as an adjunctive treatment to the
carbidopa/levodopa combination in patients with PD, typically experiencing ‘off periods,’ as per the Food and Drug
Administration guidelines.
Compounds such as the COMT inhibitors have been
manufactured to increase the efficiency of central-acting
levodopa, a dopamine precursor that is peripherally broken
down by enzymes such as L-aminoacid decarboxylase
(AADC) and COMT. Previously, the clinically available
COMT inhibitors have demonstrated an increased risk of
acute liver failure (tolcapone), liver safety concerns (nebicapone), and limited efficacy with frequent dosing (entacapone).77–79 These shortcomings necessitated the development of novel COMT inhibitors such as Opicapone.

SIDE-EFFECTS OF CURRENT TREATMENTS

PROPERTIES AND GUIDELINES

Pharmacological treatments of PD cause numerous adverse
effects. MAO-B inhibitors commonly cause nausea and

Opicapone is a hydrophilic oxadiazole analog with a pyridine N-oxide at the 3rd position, providing its strong inhibitory effect while also minimizing cell toxicity.80 It is
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recommended as a 50mg once-daily oral capsule at bedtime. It is advised that patients do not have oral intake for
the hour preceding or following opicapone. This is because
peak and total drug exposure may decrease significantly following a meal when compared to fasting.81
Adjusted guidelines, utilizing the Child-Pugh scoring
system (system for measuring chronic liver disease), were
created for adult patients with hepatopathy. A patient with
mild hepatopathy (Child-Pugh A) needs no adjustments. A
patient with Child-Pugh B is recommended to have 25mg
daily at bedtime, and finally, at Child-Pugh C, patients
should avoid the use of opicapone, mainly due to lack of
data on this population.82 Guidelines for the geriatric population are similar to that of the adult population. Contraindications for opicapone include concomitant use of
MAO inhibitors, pheochromocytoma, paraganglioma, or
any other catecholamine secreting neoplasms.83
Opicapone is available in 25 or 50mg hard gelatin capsules. This drug is considered flammable and should be
stored at a temperature below 30°C.83
As of June 2016, The European Medicines Agency approved opicapone, originally developed by BIAL Pharmaceuticals, for marketing authorization throughout the European Union as an adjunct to levodopa and decarboxylase
inhibitors in PD patients and end-of-dose motor fluctuations. In April 2020, the Food and Drug Administration opicapone as an adjunctive treatment for Sinemet in PD patients experiencing “off episodes.”84
MECHANISM OF ACTION

COMT is responsible for catalyzing the methyl group transfer of S-adenosyl-L-methionine to a substrate with a catechol group. When the degradation of levodopa is prevented
by carbidopa or benserazide, COMT becomes the major metabolizing enzyme of levodopa.83 As a COMT inhibitor, opicapone inhibits the O-methylation of levodopa to 3-Omethyldopa.85 Opicapone has been found to act through
reversible and selectively peripheral COMT inhibition, decreasing the degradation of levodopa. One of the major advantages of opicapone is its selective action in the periphery, setting it apart from other COMT inhibitors, which also
act in the central nervous system.80 Finally, opicapone has
a high binding affinity, resulting in a slow dissociation rate
constant (Kd).86
PHARMACODYNAMICS AND PHARMACOKINETICS

Oral administration of opicapone has been shown to have
long-lasting COMT inhibitory action due to its slow, complex dissociation rate.87,88 This inhibitory action was found
to last longer than other COMT inhibitory drugs such as entacapone.78 A study conducted by Almeida et al. has shown
that opicapone has a dose-dependent increase in peak
serum concentration (Cmax) and overall drug exposure
within the bloodstream (AUC).81 Opicapone, when combined with Prolopa®, has been shown to increase the Cmax
of levodopa and benserazide; however, it has not shown
similar effects when combined with DA agonists or MAO B
inhibitors.82,89

Studies have shown that opicapone inhibition of COMT
may be dose-dependent. In such studies, a 10mg opicapone
dose elicited 36.1% inhibition.90 Total inhibition of 100%
was elicited by 200mg or greater.91 Half-life was found to
be between 0.8 (50mg) and 3.2 (1200mg) hours; however, as
mentioned above, COMT inhibitory effect of opicapone can
be detected even after 24 hours due to the compound’s slow
dissociation rate.91
Elimination of opicapone has been shown to be accomplished through sulfation at the hepato-biliary system by
the BIA 9-1103 enzyme.92 This has been supported by the
fact that opicapone levels have been shown to be elevated
in patients with moderate liver impairment.93 The maximum urinary excretion rate is said to occur within 4 hours
of dose and continues to rise in a less than dose-proportional manner.81 Opicapone is primarily excreted through
the feces (70%) and expired air (20%).93
At 25mg, 50mg, and 75mg, the use of opicapone has
demonstrated increased levodopa availability when compared to placebo or entacapone.93 Finally, due to the longlasting effects of opicapone, it is recommended that opicapone be taken only once daily. Further, since levodopa
dosing may require several doses throughout the day, opicapone is recommended to be taken at bedtime, allowing
for easily modifiable levodopa regimens without concern for
potential absorption interactions.94
According to a randomized, double-blind, placebo-controlled study comparing the pharmacokinetics of opicapone
in Japanese and white subjects, neither ethnicity, age, nor
sex influenced drug effects.95 The FDA further elaborates
that there were no clinically significant differences in the
pharmacokinetics of opicapone when comparing Japanese,
Caucasian, Asian, or Black populations.83
SIDE EFFECTS AND ADVERSE EVENTS

The controlled, double-blind, randomized phase III study
BIPARK-I investigated the effects of incremental dosages
(5, 25, 50mg) of opicapone compared to placebo and entacapone.96 This study found that all doses had the potential to elicit dyskinesia, with 50mg dose producing the most
prominent signs.96 Dyskinesia was the most common side
effect and generally occurred within the first three weeks.96
It was unclear whether the dyskinesia was related to the increased levodopa levels or the direct effect of opicapone.
A follow-up study BIPARK-II found similar results.97 In a
pooled analysis of these two similarly designed studies, adverse events such as insomnia, dry mouth, dizziness, constipation, and elevated creatine phosphokinase were all
recorded. There is concern that adverse events may ensue
in patients with hepatopathy due to the possibility of increased plasma concentration.98

OPICAPONE IN PARKINSON’S TREATMENT
CLINICAL DATA

–

EFFICACY

Data on the efficacy of opicapone in PD patients with motor
fluctuations come from the results of several clinical trials
to date, including BIPARK-I, BIPARK-II, their open-label
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extensions, and the OPTIPARK open-label study (Table 1 &
2).82,88,96,99–102 For Phase II trials, two double-blind studies were conducted involving a total of 45 PD patients with
motor fluctuations.82,88,102 The first study was a multi-center, double-blind, randomized, placebo-controlled study of
opicapone in 40 patients (20 female) with diagnosed idiopathic PD.88 Data were evaluated from 35 subjects. Patients had a modified Hoen and Yahr stage of less than 5
in the OFF state, and the mean age was 67.5 years.103 Efficacy measures were reported following administration of 5,
15, and 30 mg doses of opicapone compared to placebo. Following the 4-week double-blind treatment period, significant changes from baseline were found in motor responses
as recorded in patient diaries, including absolute OFF time
and ON time without dyskinesia.88 A significant change in
absolute OFF time of -145.0 minutes was reported for the
30 mg dose compared to placebo. Treatment with opicapone
was also found to decrease the ‘time to ON’ and ‘time to
best-ON’ compared to placebo, but these changes were not
significantly different from the placebo.88 The next Phase
II trial was a 3-center, double-blind, randomized, placebocontrolled crossover study of opicapone in 10 patients (4 f)
with diagnosed idiopathic PD.102 Patients had a modified
Hoen and Yahr stage of less than 5 in the OFF state, and
the mean age was 58.4 years.103 On day 3 of the study, several significant efficacy measures were reported following
the administration of 25, 50, and 100 mg doses of opicapone
compared to placebo. The ON-time duration was found to
have increased 18% with the 25 mg dose, and 25% with the
50 mg dose.102 The duration of ON time without dyskinesias also increased more than 100% following administration of the 25mg dose, and 73% with the 50mg dose. In addition, there was a notable 49% increase in ON time with
dyskinesias with the 100mg dose.102
Two Phase III trials to date plus their open-label extensions have yielded efficacy results for opicapone.82,96,100,101 The first was BIPARK-1, a randomized,
double-blind, placebo-controlled, and active-controlled
trial of opicapone in 600 PD patients with end-of-dose motor fluctuations.96 Repeated oral doses of 5, 25, and 50 mg
were investigated alongside an active comparator entacopone 200mg and placebo over 14-15 weeks. The 50 mg opicapone dose was found to be superior to placebo and noninferior to entacapone 200mg for reducing OFF symptoms.
The mean change in ‘time in the OFF state’ was -116.8 minutes with 50 mg opicapone and -56 min with placebo. In
addition, the mean change in OFF state with 5 and 25 mg
doses did not differ from placebo.96 The next study was BIPARK-2, a randomized clinical double-blind placebo-controlled study of opicapone in 427 patients (169 f) with diagnosed PD for at least 3 years.100 Patients had a modified
Hoen and Yahr stage of 1 to 3, and the mean age was 63.1
years. Either a 25 or 50 mg dose of opicapone or placebo was
taken in the evening, at least 1 hour after the last dose of
levodopa. Primary efficacy analysis showed that 50 mg opicapone was superior for the reduction of OFF-time compared to placebo (-54 min).100 In addition, the 25 and 50
mg doses showed no significant increase ‘ON time without
dyskinesia’ compared to placebo. The double-blind phase of
the study lasted 14-15 weeks, followed by an open-label period lasting one year that was completed by 286 patients. At

the end of the open-label period, the 50 mg once-daily dose
was found to be associated with a significant reduction in
mean daily OFF-time maintained for at least one year.100
A subsequent pooled analysis of combined patient data
from both the double-blind and open-label portions of BIPARK-I and BIPARK-2 yielded further information about the
efficacy of opicapone.101 From the analysis of the doubleblind phase, the mean treatment effect versus placebo was
-35.1 minutes and -58.1 minutes in absolute daily OFF time
for 25 mg and 50 mg doses, respectively. Significant reductions in OFF time were found, as were significant increases
in ON time.101 From the analysis of the open-label phase,
341 patients switched doses from 25mg to 50gm opicapone,
and 12 patients reduced the dose to 5 mg. The patient diary
results of patients assigned to 50 mg in the double-blind
phase indicated maintenance of treatment effects throughout the open-label phase. Patients and providers both noted
qualitative improvements in motor fluctuations during the
open-label phase, indicating maintenance of treatment effects via questionnaires and rating scales (i.e., PGI-C: Patient Global Impression of Change; UPDRS: Unified Parkinson’s Disease Rating Scale; PDQ-8: Parkinson’s Disease
Questionnaire; CGI-C: Clinician’s Global Impression of
Change).101 Remarks have also been published regarding
the methodologies of the opicapone Phase III studies.104,105
The most recent clinical trial of opicapone was OPTIPARK, a prospective open-label, single-arm, multi-center
study of opicapone in 502 patients with diagnosed PD and
Hoehn and Yahr stage I-IV during ON periods.99 Of the 495
treated patients (179 females) the mean age was 67.7 years.
All patients were undergoing treatment with 3–7 daily
doses of levodopa, and none were currently or previously
taking tolcapone or entacapone. After 3 months, 71.3% of
patients experienced an improvement in the Clinician’s
Global Impression of Change (CGI-C), and 76.9% experienced an improvement after 6 months. The primary endpoint of the OPTIPARK study was CGI-C, but significant improvements in secondary assessments included the UDPRS
parameter ‘activities of daily living during OFF’ (mean ± SD:
-3.0 ± 4.6) and ‘motor scores during ON’ (-4.6 ± 8.1), as well
as PDQ-8 score (-3.4 ± 12.8) and NMSS score (-6.8 ± 19.7).99
Opicapone was generally well-tolerated, and the most frequent side effect was dyskinesia (11.5%).99
SAFETY AND ADVERSE EVENTS

No remarkable side effects were reported in Phase I studies
of single or repeated doses of opicapone.81,92 In patients
with moderate chronic hepatic impairment (Child-Pugh
category B, score 7-9), the bioavailability of a single 50mg
dose of opicapone was found to be significantly higher at
72 hours compared to healthy controls.92 This finding supports the hypothesis that opicapone undergoes hepatobiliary excretion and may be subject to first-pass effects. No
dose adjustment was recommended for patients with mild
to moderate chronic hepatic impairment as a result of this
finding.92 It was noted, however, that levodopa and/or opicapone dosage may require adjustment in select patients
due to the potential for enhanced levodopa dopaminergic
responses.92 No serious cases of hepatoxicity were reported
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Table 2. Comparative Studies
Ferreira et al.
2016
(BIPARK-1)96
Phase III

600 PD patients with
end-of-dose motor
fluctuations; repeated
oral doses (5, 25, 50
mg) with active
comparator
entacopone 200mg
over 14-15 weeks.

50 mg opicapone was superior to placebo and
non-inferior to entacapone 200mg for reducing
OFF symptoms. Mean change in 'time in the
OFF state' was -116.8 minutes with 50 mg
opicapone and -56 min with placebo. Mean
change in OFF state with 5 and 25 mg did not
differ from placebo.

in the BIPARK-I or BIPARK-II clinical trials, or their openlabel extensions.96,101,106,107 Regarding cardiac effects,
Holter monitoring before and after single oral doses of opicapone found that neither 50 mg nor 800 mg caused significant QTc prolongation.108
Pooled analysis of the BIPARK-I and BIPARK-II studies
showed that the adverse effects of opicapone treatment included dyskinesia, insomnia, dry mouth, dizziness, constipation, and blood creatine phosphokinase elevation.82,101,109 No serious adverse events were reported in
the open-label extension periods of these trials. Dyskinesia
was the most commonly reported side effect across both BIPARK study double-blind phases, with 17.7% in the combined opicapone groups versus 6.2% with placebo.101 Dyskinesia was also the most frequently reported side effect in
the OPTIPARK open-label study, occurring in 11.5% patients.99 Among the total treatment-emergent adverse effects (TEAEs) reported in the results of the OPTIPARK
study, the most common TEAE was also dyskinesia (n=57),
followed by dry mouth (n=32), dizziness (n=24), nausea
(n=22), and constipation (n=20).99 The TEAE most frequently leading to discontinuation in OPTIPARK was nausea (n=10). A total of 34 serious TEAEs occurred in OPTIPARK, and 7 of these were treatment-related. In addition,
total of 84 TEAEs leading to discontinuation were reported,
and 66 of these were treatment-related.99
Current prescribing information indicates that opicapone (Ongentys®) is absolutely contraindicated in patients taking non-selective monoamine oxidase (MAO) inhibitors, or in patients with pheochromocytoma
paraganglioma, or other catecholamine secreting neoplasms.83,110 A summary of clinical efficacy and comparative studies can be seen in Tables 1 and 2.

CONCLUSION
PD is a common neurodegenerative disease with an increasing prevalence in increasing age. It is a common source of
disability and morbidity and the fastest-growing neurodegenerative disorder today. The leading pathophysiological
theory involves the loss of dopaminergic neurons, mostly in
the basal ganglia, as well as the death of cholinergic, serotonergic, and noradrenergic neurons. These neuronal losses
are not limited to the central nervous system, but also occur
in the gut. Several molecular factors have been identified
that may contribute to the pathogenesis, and studies are
underway.
Though no definite inheritance pattern for PD has been
determined, family history remains the strongest risk factor. Other risk factors include depression, dairy consump-

50mg opicapone treatment
was non-inferior to
entacapone with a similar
safety profile. Consider
adding opicapone at
bedtime for patients with
PD and end-of-dose motor
fluctuations.

tion, and exposure to environmental toxins, whereas caffeine and smoking may have a protective role. The clinical
presentation of PD includes stereotypical movement disorders, bradykinesia, rigidity gait disturbances, and postural
instability. It also spans genitourinary symptoms, constipation, and sleep disorders, as well as cognitive and psychiatric deterioration. While official diagnosis can only be
made post-mortem with the detection of Lewy Bodies in an
autopsy, diagnoses are usually made based on clinical presentation with the aid of imaging and the response to levodopa treatment.
Traditional pharmacotherapy is based on increasing
dopamine and acetylcholine effect to overcome the loss of
neuronal activity and includes a central role for levodopa.
Unfortunately, as the natural course of PD progresses, patients being to experience periods of return of symptoms,
despite therapy; these symptoms, referred to as “off
episodes,” usually correlate with decreased medication activity and are alleviated with the next medication dose.
Such “off episodes” are a source of great discomfort and
morbidity in PD patients. Opicapone is a novel peripheral
COMT inhibitor that is used in combination with standard
treatment to prevent and alleviate these episodes. It acts by
decreasing the metabolism of levodopa and has a synergistic effect. It was mainly developed to increase efficacy and
avoid common side effects with previous generation COMT
inhibitors. It has been approved as an adjunct therapy for
PD treatment since 2016, and recently gained FDA approval
for use in the USA.
Opicapone is approved for use with a single nightly 50mg
dose, or a reduced 25mg dose in hepatic dysfunction (ChildPugh B); due to lack of evidence, it should be avoided in
patients classified as Child-Pugh C. Opicapone has been
studied in several clinical trials, both versus placebo and entacapone, and found to be effective and safe. It was able
to significantly extend the activity of levodopa, and decrease the duration of “off episodes” by about 50 daily minutes on average with a single 50mg nightly dose. The more
recent OPTIPARK study also demonstrated significant improvement in the quality of life of patients taking opicapone, along with improvement in objective indices.
Opicapone use is not without risk, and the leading side
effect is dyskinesia. Though it is considered safe for use in
hepatic dysfunction, more evidence is likely needed to support this claim, and after-marketing studies will be required
to elucidate safety in this and the general population.
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Table 1. Clinical Efficacy and Safety
Author (Year)

Groups Studied and
Intervention

Results and Findings

Conclusions

Almeida et al.
201381
Phase I

64 young healthy
male volunteers;
single rising oral
doses (10, 25, 50,
100, 200, 400, 800
and 1200 mg).

Well tolerated at all doses tested; dosedependent maximum COMT inhibition,
36.1 - 100% (10 to ≥ 200 mg); 72hrs postdose COMT inhibition, 5.9 to 54.6% (10 –
800 mg).

Opicapone appears to be well
tolerated at doses higher than 50
mg; systemic exposure to opicapone
and its metabolites may increase
proportional to dose. Dosage may
safely be increased in select patients
if poor response to starting 50 mg
dose.

Almeida et al.
201381
Phase I

12 young healthy
male volunteers;
single oral doses
(50 mg).

Significantly lower drug concentration
(238-635ng/mL) after standard breakfast
compared to fasting.

Systemic exposure to opicapone and
its metabolites may decrease after a
meal. Be aware of the current
clinical recommendation to take
opicapone at bedtime.

Rocha et al.
2016102
Phase II

10 PD patients
with motor
fluctuations; single
oral doses (25, 50,
100 mg)

Dose-dependent increase in levodopa
plasma concentration; well tolerated with
standard-release 100/25 mg
levodopa+carbidopa or benserazide.
Decreased 'time to best ON' and increased
'ON duration.'

In select patients with poor response
to 50 mg, consider increasing
opicapone dose with the aim of
increasing circulating levodopa.

Ferreira et al.
201588
Phase II

35 PD patients
with motor
fluctuations;
repeated oral
doses (5, 15, 30
mg)

Dose-dependent increase in levodopa
plasma concentration; decrease in
absolute 'OFF' time with 30 mg (-145 min),
increased 'ON time without dyskinesia.'

Lower doses of opicapone may have
less impact on motor fluctuations in
PD patients. Expect longer 'OFF' and
shorter 'ON' periods if opicapone
dose is reduced below 30 mg.

Lees et al.
2017
(BIPARK
2)106
Phase III

427 PD patients
with end-of-dose
motor fluctuations;
repeated oral
doses (25, 50 mg)
compared to
placebo over 14-15
weeks.

50 mg opicapone was superior for
reduction of OFF time compared to
placebo (-54 min); 25 and 50 mg opicapone
did not significant increase 'ON time
without dyskinesia' compared to placebo.

Opicapone 50mg once daily reduces
OFF time in PD patients with motor
fluctuations taking levodopa.
Opicapone may be considered as a
once daily COMT inhibitor, as it
appears safe and well tolerated up to
1 year.

Ferreira et al.
2019
(BIPARK-1
and
BIPARK-2
open-label
extension)101
Phase III

662 PD patients
with end-of-dose
motor fluctuations;
repeated oral
doses (25, 50 mg)
compared to
placebo over a 1
year open-label
study period.

Mean treatment effect versus placebo was
– 35.1 min and -58.1 min reduction in
absolute daily OFF time for 25 mg and 50
mg, respectively. Switching 25mg to 50gm
or placebo to opicapone improved motor
fluctuations. Patients and providers noted
maintenance of effect.

Opicapone was found to be safe and
efficacious for up to 1 year, and may
be a viable long-term option for PD
patients with end-of-dose motor
fluctuations. Data suggest that
patients may respond positively to
the new drug regimen.

Reichmann et
al. 2020
(OPTIPARK
open-label)99
Phase IV

495 treated
patients with PD
and motor
fluctuations; 50 mg
once daily at
bedtime added to
existing PD
treatment for 3 or
6 months.

After 3 months, 71.3% of patients
experienced any improvement in
Clinician's Global Impression of Change
(CGI-C), 76.9% after 6 months. Significant
improvements also reported in PGI-C,
UPDRS, and PDQ-8.* Generally welltolerated; most frequent side effect
dyskinesia (11.5%).

Addition of opicapone to levodopa
treatment may improve patient
perceptions of their global PD
condition. Clinicians also may notice
improvement. Consider opicapone in
patients not already taking a COMT
inhibitor.

* PGI-C: Patient Global Impression of Change, UPDRS: Unified Parkinson’s Disease Rating Scale PDQ-8: Parkinson’s Disease Questionnaire CGI-C: Clinician’s Global Impression of
Change
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